First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
Condition(s):HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract CancerLast Updated:March 1, 2023Not yet recruiting